Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B

Endocrinology

Volumn 150, Issue 7, 2009, Pages 3076-3082

  Zhang, Ren ^a   Maratos Flier, Eleftheria ^a   Flier, Jeffrey S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHODIESTERASE IV; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENERGY BALANCE; ENZYME DEFICIENCY; GENE REPRESSION; LIPID DIET; LOCOMOTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; CELL SIZE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DIETARY FATS; ENERGY METABOLISM; LEPTIN; MALE; MICE; MOTOR ACTIVITY; PANNICULITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649667009     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0108     Document Type: Article

References (68)

1. Taubes G 1998 As obesity rates rise, experts struggle to explain why. Science 280:1367-1368 (Pubitemid 28264815)
2. Popkin BM, Doak CM 1998 The obesity epidemic is a worldwide phenomenon. Nutr Rev 56:106-114 (Pubitemid 28209802)
3. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB 1999 Annual deaths attributable to obesity in the United States. JAMA 282:1530-1538 (Pubitemid 29504046)
4. Billington CJ, Epstein LH, Goodwin NJ, Hill JO, Pi-Sunyer JX, Rolls BJ, Stern J, Wadden TA, Weinsier RL, Wilson GT, Wing RR, Yanovski SZ, Hubbard VS, Hoofnagle JH, Everhart J, Harrison B 2000 Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 160:898-904
5. Spiegelman BM, Flier JS 2001 Obesity and the regulation of energy balance. Cell 104:531-543 (Pubitemid 32201948)
6. Flier JS 2004 Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337-350 (Pubitemid 38167322)
7. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661-671 (Pubitemid 30205071)
8. Barsh GS, Farooqi IS, O'Rahilly S 2000 Genetics of body-weight regulation. Nature 404:644-651 (Pubitemid 30205069)
9. Rosen ED, Spiegelman BM 2000 Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16:145-171 (Pubitemid 32037503)
10. Ahima RS, Flier JS 2000 Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327-332 (Pubitemid 30729003)
11. Mohamed-Ali V, Pinkney JH, Coppack SW 1998 Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145-1158 (Pubitemid 28548534)
12. Trayhurn P, Beattie JH 2001 Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60:329-339 (Pubitemid 32772448)
13. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA 2001 The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280:E827-E847 (Pubitemid 32553225)
14. Flier JS 1995 The adipocyte: storage depot or node on the energy information superhighway? Cell 80:15-18
15. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
16. Feinstein R, Kanety H, PapaMZ,Lunenfeld B, KarasikA1993Tumornecrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268:26055-26058 (Pubitemid 2013440)
17. Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278
18. Fried SK, Bunkin DA, Greenberg AS 1998 Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850 (Pubitemid 28496456)
19. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y 1996 Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800-803 (Pubitemid 26225097)
20. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
21. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 82:4196-4200 (Pubitemid 27525539)
22. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S 1996 Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110
23. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830
24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante JrAW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808 (Pubitemid 38063703)
25. Shoelson SE, Lee J, Goldfine AB 2006 Inflammation and insulin resistance. J Clin Invest 116:1793-1801 (Pubitemid 44033299)
26. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH 2008 The metabolic syndrome. Endocr Rev 29:777-822
27. Dandona P, Aljada A, BandyopadhyayA2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7 (Pubitemid 38032801)
28. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444: 860-867 (Pubitemid 46024993)
29. Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119 (Pubitemid 40629025)
30. Eckel RH, Grundy SM, Zimmet PZ 2005 The metabolic syndrome. Lancet 365:1415-1428 (Pubitemid 40523737)
31. Pickup JC 2004 Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-823 (Pubitemid 38280558)
32. Moller DE 2000 Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212-217 (Pubitemid 30603166)
33. Houslay MD, Adams DR 2003 PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18 (Pubitemid 36259414)
34. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C 2003 Cyclic AMPspecific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496 (Pubitemid 36800786)
35. Houslay MD, Sullivan M, Bolger GB 1998 The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting antiinflammatory and antidepressant actions. Adv Pharmacol 44:225-342
36. Conti M, Jin SL 1999 The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acids Res Mol Biol 63:1-38
37. Hatzelmann A, Schudt C 2001 Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279 (Pubitemid 32242587)
38. Houslay MD, Schafer P, Zhang KY 2005 Keynote review: phosphodiesterase- 4 as a therapeutic target. Drug Discov Today 10:1503-1519 (Pubitemid 41527193)
39. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG 1997 Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18:164-171
40. Jin SL, Conti M 2002 Induction of the cyclic nucleotide phosphodiesterase PDE4Bis essential for LPS-activatedTNF-α responses. Proc Natl Acad SciUSA 99:7628-7633 (Pubitemid 34568742)
41. Jin SL, Lan L, Zoudilova M, Conti M 2005 Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531
42. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, ContiM1999 Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96:11998-12003 (Pubitemid 29502847)
43. Honnor RC, Dhillon GS, LondosC1985 cAMP-dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. J Biol Chem 260:15122-15129 (Pubitemid 16148001)
44. Rodbell M 1964 Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375-380
45. Cherry JA, Davis RL 1999 Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287-301 (Pubitemid 29162777)
46. Iona S, Cuomo M, Bushnik T, Naro F, Sette C, Hess M, Shelton ER, ContiM 1998 Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 53:23-32 (Pubitemid 28068369)
47. Lobban M, Shakur Y, Beattie J, HouslayMD1994 Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem J 304(Pt 2):399-406 (Pubitemid 24368217)
48. Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G 2000 Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20:349-374
49. Siuciak JA, McCarthy SA, Chapin DS, Martin AN 2008 Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 197:115-126
50. Friedman JM, Halaas JL 1998 Leptin and the regulation of body weight in mammals. Nature 395:763-770 (Pubitemid 28485436)
51. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432 (Pubitemid 24365442)
52. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83 (Pubitemid 29299050)
53. Hu E, Liang P, Spiegelman BM 1996 AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703 (Pubitemid 26145805)
54. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 Anovel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749
55. Wang H, Edens NK 2007 mRNA expression and antilipolytic role of phosphodiesterase 4 in rat adipocytes in vitro. J Lipid Res 48:1099-1107 (Pubitemid 46708677)
56. Gronning LM, Baillie GS, Cederberg A, Lynch MJ, Houslay MD, Enerback S, Tasken K 2006 Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice. FEBS Lett 580:4126-4130
57. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA 2005 The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 46:494-503 (Pubitemid 43109786)
58. Nakamura J, Okamura N, Kawakami Y 2004 Augmentation of lipolysis in adipocytes from fed rats, but not from starved rats, by inhibition of rolipramsensitive phosphodiesterase 4. Arch Biochem Biophys 425:106-114 (Pubitemid 38479609)
59. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK 2006 Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166: 902-908
60. Ofei F, Hurel S, Newkirk J, SopwithM,TaylorR1996 Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885 (Pubitemid 26225502)
61. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ 2000 No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316-1319 (Pubitemid 32269392)
62. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C 2005 Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42:517-525 (Pubitemid 41527607)
63. Bruss MD, Richter W, Horner K, Jin SL, Conti M 2008 Critical role of PDE4D in β2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts. J Biol Chem 283:22430-22442
64. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM 2008 Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33:1611-1623 (Pubitemid 351684706)
65. HuangZ, Ducharme Y, Macdonald D, RobichaudA2001 The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5:432-438 (Pubitemid 32900516)
66. Dastidar SG, Rajagopal D, Ray A 2007 Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8:364-372 (Pubitemid 46700993)
67. Lipworth BJ 2005 Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-175 (Pubitemid 40091808)
68. Giembycz MA 2000 Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59:193-212